Stocktoria
Hims & Hers Health, Inc. HIMS
Hims & Hers Health, Inc. (HIMS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $2.3B at a 5.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-01 | Canaccord Genuity | Buy (main) |
| 2026-07-01 | B of A Securities | Neutral (main) |
| 2026-06-18 | Barclays | Overweight (main) |
| 2026-05-26 | B of A Securities | Neutral (main) |
| 2026-05-22 | Truist Securities | Hold (main) |
| 2026-05-19 | B of A Securities | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.169 |
| Retained earnings / assets | -0.053 |
| EBIT / assets | 0.049 |
| Equity / liabilities | 0.335 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc. | 4/9 | 1.61 | 61.2 | +59% |
| TDOC | Teladoc Health, Inc. | 5/9 | -16.73 | — | -1.5% |
| TOI | Oncology Institute, Inc. | 4/9 | -5.27 | — | +27.8% |
| LFMD | LifeMD, Inc. | 5/9 | -9.85 | 13.9 | +25.3% |
| SBC | SBC Medical Group Holdings Inc | 3/9 | 8.55 | 6.7 | -15.5% |
| AIRS | Airsculpt Technologies, Inc. | 3/9 | -0.63 | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | 6/9 | -3.98 | — | +25.2% |
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
FAQ
Is HIMS financially healthy?
Hims & Hers Health, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does HIMS pay a dividend?
No, Hims & Hers Health, Inc. does not currently pay a dividend.
How profitable is HIMS?
In FY2025, Hims & Hers Health, Inc. had a net margin of 5.5% and a return on equity of 23.7%.
What is HIMS's P/E ratio?
Hims & Hers Health, Inc.'s trailing price-to-earnings (P/E) ratio is about 61.2×, based on its latest annual earnings.
What is the analyst price target for HIMS?
The average Wall-Street price target for Hims & Hers Health, Inc. is $28.35, about 5.4% below the recent price, from 13 analysts (consensus: hold).
Is HIMS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Hims & Hers Health, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the grey zone, a P/E of about 61.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.